A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc.
GlaxoSmithKline
A2 Biotherapeutics Inc.
Ohio State University Comprehensive Cancer Center
Revolution Medicines, Inc.
University of Colorado, Denver
University of Nebraska
Natera, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
Massive Bio, Inc.
Washington University School of Medicine
Guardant Health, Inc.
University of California, San Francisco
ModeX Therapeutics, An OPKO Health Company
Stanford University
Charite University, Berlin, Germany
Glasgow Royal Infirmary